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Abstract: Recent advances in the field of meta-omics sciences and related bioinformatics tools
have allowed a comprehensive investigation of human-associated microbiota and its contribution
to achieving and maintaining the homeostatic balance. Bioactive compounds from the microbial
community harboring the human gut are involved in a finely tuned network of interconnections with
the host, orchestrating a wide variety of physiological processes. These includes the bi-directional
crosstalk between the central nervous system, the enteric nervous system, and the gastrointestinal tract
(i.e., gut–brain axis). The increasing accumulation of evidence suggest a pivotal role of the composition
and activity of the gut microbiota in neurodegeneration. In the present review we aim to provide
an overview of the state-of-the-art of meta-omics sciences including metagenomics for the study
of microbial genomes and taxa strains, metatranscriptomics for gene expression, metaproteomics
and metabolomics to identify and/or quantify microbial proteins and metabolites, respectively.
The potential and limitations of each discipline were highlighted, as well as the advantages of an
integrated approach (multi-omics) to predict microbial functions and molecular mechanisms related
to human diseases. Particular emphasis is given to the latest results obtained with these approaches in
an attempt to elucidate the link between the gut microbiota and the most common neurodegenerative
diseases, such as multiple sclerosis (MS), Alzheimer’s disease (AD), Parkinson’s disease (PD), and
amyotrophic lateral sclerosis (ALS).
Keywords: gut–brain axis; gut microbiota; meta-omics sciences; neurodegenerative diseases
1. Introduction
In the last 15 years, the growing awareness of the sustained association between the intestinal
microbiota and human health has led to many efforts to better understand its role and contribution in
the pathogenesis of various diseases.
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At birth human intestine is essentially sterile; the onset of the gut microbiota starts as a dynamic
ecosystem where the microbial composition increases both its diversity and richness until achievement
of the “mature” level in the adult [1]. At this stage, the gut microbiota is a rather heterogeneous
population including bacteria, fungi, archaea, viruses, and protozoa to an overall extent of about
1014 cells, approximately 10 times the number of cells of the human body [2]. Since its onset in the early
life, the microbiota development and composition are influenced by several host-related variables
(e.g., natural childbirth or caesarean section, genetic background, gender, age) and environmental
parameters, such as dietary habits [1,3].
Bacteria is the most represented kingdom in the gut-associated microbial community and, although
featured by a high inter-individual variability, a balanced composition of the human gastro-intestinal
tract (GIT) microbiota is mainly represented by Firmicutes and Bacteroidetes phyla, and, to a lesser
extent, by Actinobacteria, Verrucomicrobia, Proteobacteria, Fusobacteria, and Cyanobacteria phyla [4].
Bioactive compounds arising from the microbial commensals are involved in a finely tuned network of
interconnections between the host and its microbiota and among microbiota members. Several lines of
evidence have shown the ability of the microbiome to transmit signals molecules and metabolites of
microbial origin to distant organs such as the brain [5–7], orchestrating a wide variety of physiological
processes, ranging from normal homeostasis, host metabolism and immune system to brain functions.
This close interconnection is also known as “gut–brain axis” (GBA).
In this view, accumulating data suggest that alteration in the optimal microbiome composition and
activity (a condition named “microbiome dysbiosis”) may contribute to the onset of several pathologic
conditions, such as neurological and neurodegenerative disorders [8,9].
The technological progress witnessed in the last two decades has marked a profound change in
the methods employed for the study of the human microbiota and its pivotal role in both physiologic
and pathologic processes. To date, studies based on germ-free (GF) animal models, gut microbiota
manipulation with antibiotics and fecal microbial transplantation, have been performed to investigate
the modulatory effect of the microbiota on gut–brain axis and its implications in neurodegeneration.
Omics sciences, such as metagenomics, metatranscriptomics, metaproteomics, and metabolomics,
represent the last frontier in elucidating host-microbiota cross-talks, providing invaluable contributions
for unravelling this intriguing issue [10]. The integration of such systems biology-based approaches,
supported by computational and bioinformatics analyses, help to shed light on the role of microbiota
in the etiology and/or development of neurodegenerative disorders [11].
In this review, mainly taking into account peer-reviewed studies of the last five years, we aim
to provide a general description of the state-of-the-art of the investigation methods used in the
study of microbiota, with particular emphasis on meta-omics sciences such as metagenomics,
metatranscriptomics, metaproteomics, and metabolomics, along with their complementary integration
made feasible by the advances in bioinformatics tools. In addition, we focused on the latest achievements
of these approaches in elucidating the influence of gut microbiota in the onset and/or progression of
the most commonly studied forms of neurodegeneration, such as multiple sclerosis (MS), Alzheimer’s
disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).
2. Methodology
To achieve the stated aim, a detailed and in-depth search procedure was carried out.
The literature analyzed in this review includes original studies available in qualified databases,
such as Medline/Pubmed, Scopus, Web of Sciences, and Google Scholar. The literature searching
and evaluation covers the last 20 years. However, it should be noted that the oldest references are
related to the early advances in the omics sciences or definitions of diseases. The literature of the
last 10 years was mainly considered throughout the manuscript. Instead, for the list of the latest
achievements obtained from the application of meta-omics sciences (Table 1), only the last 5 years were
taken into consideration.
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Table 1. Summary of relevant meta-omics studies correlating the gut microbiota to multiple sclerosis
(MS), Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS).
The most recent studies are sorted depending on the method employed for the microbiota investigation.
Technique Description Pathology Reference
Shotgun
metagenomics
High-throughput method that
provides information on the
functional potential of the microbiota
MS
Perlejewski et al., 2016 [12]
Colpitts et al., 2017 [13]
Jovel et al., 2017 [14]
PD Bedarf et al., 2017 [15]
AD
Sanguinetti et al., 2018 [16]
Haran et al., 2019 [17]
Park et al., 2017 [18]
Cattaneo et al., 2017 [19]
ALS Blacher et al., 2019 [20]
Marker gene
approach
PCR-based amplification of 16S/18S
rRNA gene hypervariable regions
MS
Tremlett et al., 2016 [21]
Tremlett et al., 2016 [22]
Al-Ghezi et al., 2019 [23]
PD
Keshavarzian et al., 2015 [24]
Scheperjans et al., 2015 [25]
Sampson et al., 2016 [26]
Unger et al., 2016 [27]
Hill- Burns et al., 2017 [28]
Hopfner et al., 2017 [29]
Heintz-Buschart et al., 2018 [30]
AD
Minter et al., 2017 [31]
Bonfili et al., 2017 [32]
Harach et al., 2017 [33]
Peng et al., 2018 [34]
Xin et al., 2018 [35]
ALS
Zhang et al.,2017 [36]
Fang et al., 2016 [37]
Rowin et al., 2017 [38]
Brenner et al., 2018 [39]
Mazzinì et al., 2018 [40]
Metatranscriptomics
High-throughput method that
provides information on expression
patterns of a given microbial
community
ALS Blacher et al., 2019 [20]
Metaproteomics
High-throughput method that
provides information on the
functional features of the microbial
community proteins
PD Flores Saiffe Farìas et al., 2018 [41]
Metabolomics
High-throughput method for the
comprehensive study of the
metabolite array resulting from the
microbiota–host interactions
MS Al-Ghezi et al., 2019 [23]Nourbakhsh B et al., 2018 [42]
PD Unger et al., 2016 [27]
AD Sanguinetti et al., 2018 [16]Xin et al., 2018 [35]
ALS Blacher et al., 2019 [20]
A combination of key words and terms was used: microbiota/omics sciences; microbiota/
neurodegeneration; gut–brain axis/neurodegeneration. Each disease (MS, PD, AD, ALS) was
combined with all the meta-omics sciences (metagenomis, metatranscriptomics, metaproteomics,
metabolomics), respectively.
The references of all identified articles and recent review articles were cross-checked to ensure a
valid and effective search.
3. The Microbiome Investigation in the “Meta-Omics Era”
The technological progress of the last decades has marked enormous changes in the methodology
adopted for the investigation of the microbiota and its relationship with the host, moving from the
traditional culture-based approach to the omics sciences.
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Conventional culture-based methods fail to identify all the microorganisms that make up the
microbiota and are limited to analyze and elucidate up to only 10%–30% of the cultivated microbial
community both in terms of composition and functions [43,44].
Based on a holistic perspective, omics and meta-omics sciences, including shotgun metagenomics,
metatranscriptomics, metaproteomics, and metabolomics, use attractive and powerful tools to
characterize the microbial consortia, investigate functions and dynamics, and quantify the biomolecules
they produce. In this perspective, the resident microbial genomes (metagenome), transcripts
(metatranscriptome), proteins (metaproteome), and metabolites (metabolome) are investigated in the
human frame, providing a comprehensive overview of the complex network of interconnections that
regulate the functional dynamics of each anatomical district [43,45].
These techniques provide detailed information on taxa strains of the microbial population,
evaluate potential microbial functions and molecular networks, and quantify their protein and
metabolic products. In addition, the application of these meta-omics approaches to clinical samples
has identified microbial species, protein and metabolic pathways that could be associated with the
development and treatment of human diseases.
The main challenge of the omics-based microbiome studies relies on the strong computational
effort required to deal with the impressive amount of data generated by the constantly improving next
generation sequencing (NGS) and mass spectrometry (MS) technologies [46].
On the other hand, the integration of such omics sciences in the so-called multi-omics approach,
provides more evidence of biological mechanisms and, ultimately, opens new perspectives for the
development of novel therapeutic strategies and personalized medicine.
The technical aspects of omics sciences have been widely described elsewhere [10,47–49].
The following paragraphs will provide an overview of the elective technologies used in the study
of the gut microbiota and its crosstalk with the brain, and how these disciplines have contributed to
elucidate the link between the human microbiota and neurodegenerative diseases.
3.1. Metagenomics
Metagenomics is a community-based powerful tool that studies the microbial genomes collected
from the ecological niche (e.g., the gut) where the microorganisms coexist, in order to describe the
phylogenetic, physical, and functional features of the microbiota, in a culture-independent manner.
Current metagenomics techniques are based on the shotgun approach in order to provide a
microbial community census starting from reads from DNA and alignment with reference genomes [43].
In parallel, phylogenetic composition of the microbial community has been mostly investigated by
targeted sequencing of species-specific genes.
Here, targeted sequencing of the 16S rRNA (prokaryotes) or 18S rRNA (eukaryotes) gene is one
of the most attractive strategy for a reliable and cost-effective investigation of the overall microbial
community diversity [50]. The obtained data are compared with curated taxa databases in order to
cluster the analyzed reads into operational taxonomic units (OTUs) [51]. This “marker gene” approach,
based mainly on PCR techniques, offers several advantages: it is time- and cost-efficient, and is very
sensitive to the specific marker gene analyzed [49,50,52]. Similarly, it shows some limits. In fact,
since the analysis concerns a single gene, important information such as the complexity of the entire
microbial community in the sample and the potential functional characteristics related to taxonomic
classes are lost [53].
Shotgun metagenomics, instead, by sequencing all the microbial genomes, allows for a more
complete picture of the functional gut microbiota overcoming the marker-gene limitations [54].
The investigation of the whole metagenome is based on the construction of the metagenomics
library following DNA extraction and cloning [55]. The metagenomics library is then subjected to
sequence- and/or function driven-analysis. The first approach provides a catalogue of the identified
genes and genetic elements (e.g., mobile genetic elements) to allow the taxonomical assessment of
the microbiome; in addition the function-driven analysis also provides an in-depth prediction of the
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potential function of the microbial community as assessed through the investigation of the functions
attributable to the identified genes [56].
Thus, in general, metagenomic sequencing not only provides accurate information on the microbial
composition and family classification, but can also allow functional annotation, and gene de novo
prediction [55,57]. Nevertheless, metagenomics results are limited to information on gene sequences
without considering the functional effectors such as transcripts and protein products [43]. Furthermore,
the metagenomics sequencing cannot discriminate between genes from actually active or even dead
bacterial populations, hence cannot provide sufficient information about microbiota functions; rather
draft the functional potential of a given microbial consortia [43]. Moreover, metagenomics data may
not have a very high genome coverage losing information on less abundant microorganisms [55,58].
Metagenomics studies should be supported by the constant updating of curated reference
databases and calculation sequencing algorithms. The choice of database is a fundamental step.
The Human Microbiome Project has provided a database of bacterial genome information useful
to predict OUT functions [59]. Preferred curated databases to study the human gut microbiota
include RefSeq [60] and MetaHit [61]. A wide number of bioinformatics tools are nowadays dealing
with metagenomics sequences, enabling an integrative approach between omics data. Commonly
used tools for metagenomics functional analysis are MEGAN (MEtaGenome ANalyzer) [62], IMG/M
(Integrated Microbial Genomes/Metagenomes) [63], and MG-RAST (MetaGenome-Rapid Annotation
using Subsystem Technology) [64], Kraken [65], MetaPhlAn [66], and TIPP [67]. In addition, MG-RAST
and IMG/M are also used as data repositories and, along with NCBI (National Center for Biotechnological
Information) and EBI (European Bioinformatics Institute) represent the biggest data repositories
currently available. Although based on different algorithms and slightly different statistics, these
enable the taxonomic and functional annotation of the metagenomic sequences, and allow the
comparative evaluation of multiple datasets [68,69].
3.2. Metatranscriptomics
To overcome the metagenomics limits, metatranscriptomics is aimed at investigating the gene
expression and activity of the whole microbial community [70,71].
Despite the wide choice of techniques, metatranscriptomics studies mainly focus on mRNA
sequencing to assess which genes are expressed in the analyzed community [43]. The sequencing
technology is the same as that adopted in metagenomics; however, key differences are represented
by the selective removal of the interfering nucleic acids (e.g., DNA, t-RNA, rRNA) and the reverse
transcription of m-RNA to cDNA prior to library production and its subsequent sequencing [71].
Some limitations are related to the difficulties of obtaining sufficient amounts of RNA to be analyzed
and, mostly, separate mRNA from the other abundant RNA, such as rRNA. Lastly, metatranscriptomics
classification is limited to not enough reference databases.
As for metagenomics, bioinformatic data analysis is of fundamental importance for the
comprehensive functional characterization of the RNA molecules. In this perspective, efforts are still
required to improve and develop bioinformatics tools that integrate the metagenomics sequence with
metatranscriptomics data [72].
Simple Annotation of Metatranscriptomes by Sequence Analysis (SAMSA) was the first
open-source bioinformatics pipeline designed for metatranscriptomic data. It works with
the metagenomics (MG) RAST server, a public resource for handling both metagenomic and
metatranscriptomic data [73].
SAMSA’s latest implementation, SAMSA2, based on several tools such as DIAMOND for sequence
alignment and local databases, manages end-to-end metatranscriptome analysis for stand-alone use on
a computing cluster [74].
Along with MG-RAST, COMAN is a web-based tool to analyze metatrascriptomics data, although
both do not support mapping to reference database. MetaTrans is another open-source pipeline as well
as Anvi’o and IMP for the integrated metagenomics and metaproteomics analysis [75].
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3.3. Metaproteomics
The important role of proteomics for the effective reliable identification of the metabolically active
microorganisms has been widely recognized [76,77]. There are no doubts that protein identification is
a key step to providing information on microbiota functions [76].
Metaproteomics (also known as Community Proteomics, Environmental Proteomics, or
Community Proteogenomics) is the study of all protein samples recovered directly from
environmental sources.
Along with metabolomics, metaproteomics provides the most realistic picture of the key effectors
that directly mediate the biochemical functions operated by the organisms at the specific moment of
sampling [78,79].
The recent interest in the investigation of more complex samples, such as the gut microbiota,
leads to the advent of high-performance MS platforms, which are now the dominant approaches for
metaproteomics investigations. The actual MS technologies enable the investigation of different features
of the metaproteome, such as differential proteins expression (e.g., time or treatment dependent),
investigation of sub-proteomes (i.e., protein profile of the subcellular structures), post-translational
modification (PTM) pattern, protein–protein interactions, and absolute protein quantitation [78,79].
Although several MS-based proteomics protocols have been optimized as widely reviewed [9,80,81],
gut metaproteome is mainly investigated through a “bottom-up” approach, which allows to analyze
entire proteomes starting by peptides obtained through a proteolytic digestion (typically by trypsin)
from the extracted proteins. Peptides are usually separated first by liquid chromatography (LC) prior
to their measurement at the mass spectrometer. Different methods of sample preparation and treatment
have been developed to “resolve” the complex mixtures required for the MS analysis [76]. These are
compatible with the advanced online separation technologies (such as nano Ultra Performance Liquid
Chromatography, nUPLC) and provide a better separation of the complex mixture, thus improving
protein detection rate [82].
Following computational assistance and using protein reference databases, MS data are processed
to analyze the peptide sequences and, subsequently, provide protein identifications.
A typical MS experiment generates hundreds of thousands of fragmentation spectra and an
enormous amount of MS data that cannot be manually elaborated. Efficient bioinformatics software
and tools are currently available to perform the computational operations required to translate the
myriad of spectra into a meaningful output that is both concise and informative [78]. Commonly
used search engines are OMSSA (Open Mass Spectrometry Search Algorithm) [83], X!Tandem [84],
MASCOT [85], Andromeda [86], and SEQUEST [87]. Major tasks of these tools include quality filtering
of the raw MS spectra, peptide-spectrum matching and scoring, protein database searching, data
mining, and graphical representation of the obtained results [88].
Moreover, the bioinformatics data analysis and the availability of reference genome/metagenome
sequences is undoubtedly of paramount importance in order to obtain a comprehensive picture of the
metaproteome analyzed.
Similarly to metatrascriptomics, the availability of enough reference databases can represent one
of the technical limitations of this omics approach. In addition, robust, well-standardized protocols
should be integrated in the experimental workflow especially for quantitative metaproteomics studies,
which are still lacking [89].
3.4. Metabolomics
Metabolomics provides a snapshot of the metabolites array produced by the microbial community
at the moment of sampling, enabling a comprehensive investigation of the microbial population and
the interactions between the microbial ecosystem and its host [90]. Together with the knowledge about
genetic products obtained from mRNA studies and the metaproteomic analysis, metabolomics draws
the metabolomics profiles, elucidating the network of interactions between the host and its associated
microbiota [43] as well as providing key information on the role of each microbial member in the onset
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and/or development of specific pathological conditions [91]. Identification of the metabolites catalogue
enables a comprehensive elucidation of the ongoing physiological processes and the investigation of
the cross-talks occurring between host–microbes and among microbial species [91,92].
The main steps in metabolome investigation include the pre-resolution of the complex metabolite
mixture, following the sample lysis and/or purification of the extracted metabolites from samples
of interest. Metabolites separation is generally accomplished through high performance liquid
chromatography (HPLC) or gas chromatography (GC), enabling a wide range of metabolites to be
analyzed through high sensitivity MS platforms. Similarly to metaproteomics, metabolites identification
and their subsequent quantitation is computed on the basis of the mass spectral fingerprint and the MS
fragmentation pattern.
Nevertheless, nuclear magnetic resonance (NMR) spectroscopy is also widely used in analyses
that specifically target a reduced number of metabolites [93].
The metabolomics raw data requires complex processing steps to obtain small molecules and
metabolite identification [94]. Several databases are available such as Golm Metabolome Database [95]
and Metlin [96] for GC–MS and LC-MS data, respectively, while the Human Metabolome Database
(HMDB) allows both LC-MS and GC–MS data identification analysis [97].
3.5. Multi-Omics Approach
As we previously described, each omics technology sheds light on an important aspect of the
multifaceted microbial intestinal community, however, it is limited to a single perspective. Although
each single approach has its own limits linked to technical issues, multi-omics integration can generate
a comprehensive scenario that includes more evidence while explaining biological mechanisms
and phenomena.
In this context, insights integrated by combinations of different multi-omic sciences (metagenome,
metatranscriptome, metaproteome, and metabolome) can provide a more detailed description of
microbiota–host interactions, in order to reveal the bilateral flow of information that underlies different
diseases, including neurodegeneration.
An important task in the field of multi-omics sciences concerns the annotation and integration
of the identified molecules (DNA, RNA transcripts, proteins, and metabolites) into predicted classes,
and clustering them into functional groups. For this purpose, data repositories commonly used are
Kyoto Encyclopedia of Genes and Genomes (KEGG) [98,99], Gene Ontology (GO) [100], BioCarta.
These provide information concerning the sub-cellular localization, biological process, and molecular
function for each of the listed gene product. In addition, comprehensive repositories (e.g., KEGG),
enable browsing of the literature available for each of the selected dataset entry, link it with known
pathologies or pathogenetic mechanisms, and group the dataset entries into biochemical pathways,
allowing for a thorough and deep study of the microbial community. Several software and web-based
applications, such as Web MGA, Cytoscape, IPath, DAVID, and others are used to retrieve and integrate
functional annotation from one or a plurality of sequence repositories, providing a more comprehensive
functional annotation of the investigated microbiome [69].
4. The Gut–Brain Axis
Gut microbiota is in close connection with the central nervous system (CNS) through the GBA,
enabling a bidirectional communication from gut to brain and vice versa. Briefly, the GBA includes
the following key components: the CNS, the autonomic nervous system (ANS), the enteric nervous
system (ENS), the hypothalamic–pituitary–adrenal axis (HPA), the immune system (cytokine and
chemokines) [101,102]. Complex connections develop both anatomically and biochemically, including
direct and indirect pathways between the cognitive and emotional centers of the brain and peripheral
intestinal functions. The ANS guides the afferent and efferent neural signals between the intestine
and the brain. The HPA axis and the Vagus nerve with many spinal and vagal sensory neurons carry
information from the intestinal end to the brain stem, which, in turn, includes the hypothalamus and
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the limbic system. Similarly, projections descending from the limbic system (HPA axis) influence the
autonomic activity of the gut, especially under stress stimuli [101]. The intestinal microbiota plays
a fundamental role in the development and maturation of both the human CNS and the ENS from
the first postnatal weeks. For example, the interaction between the intestinal microbiome and the
gastrointestinal mucosa membrane helps to refine and strengthen the developing immune system [103].
Biologically active neurochemical molecules of bacterial origin provide a mechanistic basis on
how the microbiota may influence brain homeostasis and physiological processes [104].
Much research on the brain–gut microbiota axis is based on the use of GF animals. Many of
these studies suggest that the intestinal microbiota produces relevant levels of neurotransmitters that
are, in part, responsible for many aspects of brain health and disease [102,105]. For instance, several
species of Lactobacillus and Bifidobacterium produce microbial metabolites, such as gamma-aminobutyric
acid (GABA), which is the main inhibitory neurotransmitter in the brain. Candida, Escherichia, and
Enterococcus produce the neurotransmitter serotonin (5-HT), while some species of Bacillus secrete
dopamine. In particular, 5-HT has different roles. In the peripheral system, it is involved in the
regulation of gastrointestinal secretion, motility (e.g., contraction and relaxation smooth muscle), and
pain perception, while in the brain 5-HT is involved in regulating mood and cognition. The gut
microbiota also plays an important role in the metabolism of tryptophan, precursor of 5-HT production,
and in the stimulation of enterochromaffin cells, which are the main producers of 5-HT in the intestinal
mucosa (about 95%) [102,106]. Bacteria fermenters produce short-chain fatty acid (SCFAs), such as
butyric acid, propionic acid, and acetic acid, which are able to stimulate the sympathetic nervous
system, the release of serotonin into the mucous membranes, and affect brain memory and learning
processes [107]. In addition, bacterial products are able to stimulate enteroendocrine cells (EEC) to
produce different neuropeptides, such as peptide YY, neuropeptide Y (NPY), and substance P, that can
enter the bloodstream and affect the ENS [102].
A strong functional integrity and interplay of the GBA is required for the homeostasis of the nervous
systems. Alterations of these connections in the GBA may influence the progress of neurodegeneration
or even contribute to its onset [108,109].
4.1. Gut Microbiota and Neurodegeneration
Over recent years, accumulating evidence has suggested that the gut microbiota is involved in
neurodegeneration. The alteration of the brain–gut microbiota homeostasis could worsen the etiology,
the pathogenesis, and/or the progression of some disorders such as MS, PD, AD, ALS, and others [110].
Neurodegenerative diseases are multifaceted disorders in which a close interaction of genetic and
environmental factors seem to initiate the pathological process.
Microbial metabolites and molecules trigger and/or amplify inflammatory brain processes,
including perturbation of host immune homeostasis, alteration of blood–brain barrier and brain
structure (Figure 1).
It is well known that oxidative stress (OS) is closely related to mitochondrial dysfunctions and
is one of the main factors associated to neurodegenerations [111]. Interestingly, several lines of
evidence showed that the microbiota can interact with host cells by merging with the mitochondrial
activities [112–114]. Potential interactions between the microbiota–gut–brain axis and CNS oxidative
stress could exist. Microbiota dysbiosis could increase the levels of reactive oxygen species (ROS)
amplifying the OS scenario and neuronal inflammation. On the other hand, brain lesions, characteristic
of various neuro-pathologies, can cause changes in gut microbiota composition and functions. The close
correlation between OS–mitochondria–microbiota and neurodegenerative diseases sheds light on the
importance of gut–brain axis connections [112].
Moreover, the reduced diversity of gut microbiota during aging, also influenced by dietary habits
accumulated over the years, could have a role in the development of neurodegeneration.
It is well known that composition of microbial community changes in diversity during aging [115].
The phyla Bacteriodetes and Firmicutes remain dominant, although their relative proportions may
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change significantly. An increase in pathogenic bacteria (pathobionts) usually occurs along with a
concomitant decrease of beneficial bacteria (symbionts) [116].
Omics and multi-omics sciences support ongoing research studies to elucidate these
intriguing connections and open new perspectives for therapeutic approaches for various
neurodegenerative diseases.
The following sections describe the implications of an altered gut microbiota in some of the most
relevant neurodegenerative disorders. An overview of some recent and relevant meta-omics studies
has been proposed.
In Table 1, the most relevant meta-omics studies of the last 5 years are listed for each
discussed disease.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 20 
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4.1.1. Implications of Gut Microbiota in Multiple Sclerosis (MS)
MS is an inflammatory disease characterized by immune-mediated axon demyelination leading
to distinct signs, including autonomic and cognitive alterations as well as motor, sensory, and visual
defects [117]. It is well known that the MS pathogenesis is strictly related to an impairment of the
immune system, with significant contributions of other different factors including both genetic and
environmental variables. Therefore, due to its function in the innate immune signaling, an involvement
of the gut microbiota has also been proposed in MS [118,119].
Experimental evidence suggests that MS is also characterized by alterations of the intestinal
permeability and bile acid metabolism which may consequently further contribute to complications in
the immune regulation of the nervous system [119].
The role of intestinal dysbiosis in the onset or development of MS is currently not well understood.
Experimental observations support the hypothesis of a cross-correlation between inflammatory
demyelination of the CNS and modification of the microbiome. A few experimental evidences have
been collected from analysis based on 16S rRNA sequencing on GF mice and experimental autoimmune
encephalomyelitis (EAE) mice, a well-established mouse model of MS. [13]. In this cited study, by 16S
rRNA sequencing, the authors show reductions in several bacterial components, such as Lactobacillus,
that contribute to an impairment of immune system in fecal samples of EAE mice [13].
Recently, an integrated studied based on 16S rRNA sequencing and computational metabolomics
has revealed that basis of the beneficial effect of the use of cannabidiol for the treatment of muscle
spasticity of MS patients. The authors showed in EAE mice that cannabinoids directly prevent microbial
dysbiosis, acting by the reduction of mucin degrading bacterial species, such as Akkermansia muciniphila,
and consequently suppress neuroinflammatory processes [23].
Some few attractive studies have also been performed on human samples.
Through 16S rRNA biomarker sequencing, a characterization of gut microbiota composition has
been carried out in fecal samples of pediatric MS compared to control children matched for age and sex.
Perturbations in the gut microbial community composition have been shown in recent onset pediatric
MS [21] and subsequent relapse risk [21].
Interestingly, two shotgun metagenomics based studies have been performed on cerebrospinal
fluid of MS patients providing information about bacterial and viral composition also in such important
biofluid [12,14].
In fact, previous research studies, based on marker-16sRNA gene, have highlighted a MS
dysbiosis related to bacterial abundance such as Faecalibacterium [120] and cClostridial species [121] in
fecal samples.
The use of antibiotics cocktails or probiotics, which clearly modify the composition of intestinal
microflora commensals, improves immune responses as well as can generally attenuate the
symptomatology of the disease [122].
These results provide a basis for future studies in which the controlled microbiota modulation
could potentially contribute to the treatment of MS.
4.1.2. Implications of Gut Microbiota in Parkinson’s Disease (PD)
PD is the second common worldwide neurodegenerative disease characterized by the death of
dopaminergic neurons in the substantia nigra pars compacta (SNpc). Clinical symptoms generally
appear when significant neuronal loss has already occurred. These include characteristic signs,
especially related to the motor system, such as tremor, bradykinesia, rigidity, and postural instability.
The recognition of these symptoms is the basis for a clinical diagnosis of advanced PD. Pharmacologic
interventions are targeted at alleviating symptoms rather than preventing and/or resolving the
disease [123]. Indeed, up to 30% of patients show non-motor symptoms, including olfactory and
gastrointestinal impairments such as nausea, vomiting, and constipation [124–126]. The onset of
constipation can also precede the motor symptoms and worsens with disease progression [127,128].
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Growing experimental evidence focused on the microbiome demonstrating the potential role of
gut microbiota on the disease state, as extensively reviewed in a recent paper by Sampson et al. [129].
As it is well known, Lewy bodies, characterized by toxic alpha-synuclein (αSyn) aggregates, are
the main pathological hallmark of PD SNpc neurons [123]. It has been reported that αSyn deposition
in neurons may begin in the neurons of the intestinal submucosa [130,131].
A large number of metagenomics studies have been focused on the identification of microbial taxa
in PD gut microbiota, its taxonomic diversity and abundance. Many of these have been performed
especially in fecal samples due to the non-invasiveness of the sample collection. Although some
controversies occur in the results, it is well evident the idea of a clear correlation of alteration of gut
microbiota in PD in comparison to a healthy status. In particular, 16S rRNA analysis showed higher
prevalence of Enterobacteriaceae and reduced Prevotellaceae in fecal microbiota of PD patients compared
to age-matched controls. Interestingly, the increased abundance of Enterobacteriaceae was correlated
to the severity of postural instability and walking difficulties as well as a decrease of Prevotellaceae.
Indeed, Prevotella produces SCFA, and thiamine and folate as by-products, that promote a healthy
intestinal environment [25].
A shotgun metagenomic approach has been used by Bedarf et al. to investigate also the fecal
microbiota of PD patients and healthy participants. The observed results revealed differences in
the colonic microbiome composition and β-glucuronate and tryptophan related metabolism at an
unprecedented detail that was not achievable through other investigation techniques such as 16S rRNA
gene sequencing [15].
Further metagenomics analysis has been shown that fecal microbiota of PD patients is featured by
a decreased abundance of butyrate producing bacteria, known for their anti-inflammatory properties.
Moreover, a parallel increase of pro-inflammatory Proteobacteria has been detected in PD mucosa [24].
An integrated metagenomics and metabolomics approach has highlighted that impaired
concentrations of SCFAs, among the main metabolic products of gut-associated bacteria fermenters,
may contribute to the gut microbiota-mediated alterations. Such alterations could worsen the
ENS environment and, consequently, contribute to the gastrointestinal dysmotility of PD patients.
Particularly, the reduction in SCFAs levels, along with a decrease of Bacteroidetes and Prevotellaceae and
an increase of Enterobacteriaceae have been shown as the key players in PD fecal samples [27].
Studies performed on GF mouse models have been remarkably contributing to elucidating the
molecular mechanisms underlying the microbiota–PD connection. As stated above, alterations of gut
microbiota could be a trigger for αSyn aggregations [130,132].
Using αSyn overexpressing mice as a well-validated model for PD, it has been reported that
gut microbiota promotes motor deficits, microglia activation and neuroinflammation, and ultimately
αSyn accumulation [26]. Remarkably, colonization of αSyn-overexpressing mice with fecal microbes
from PD patients show motor impairments in comparison to αSyn-mice treated with healthy feces.
Microbiota composition of such mice highlighted taxa-related changes, specifically regarding the family
Enterobacteraceae, and in particular Proteus spp. [26] which also is one of the main bacteria involved
in the small intestinal bowel overgrowth (SIBO), a pathological condition of the small intestine. PD
patients often show a SIBO-comorbidity related to worsening motor symptoms [133].
Following an innovative approach, Flores Saiffe Farías et al. performed an in-silico framework
to associate metaproteins with the brain proteins expression through ontological labels. Out of the
metaproteome-derived data, PD was found to be associated with selected bacterial taxa, and functional
classes related with neuronal communication, DNA/RNA metabolism, and alterations in the Major
Histocompatibility Complex-I [41].
In general, it must be taken into account that PD is a multifaceted disease due to a complex
interaction among genetic and environmental factors. These studies underline a pivotal role of the
microbiome dysbiosis in PD, and further investigations are desirable to determine how it could trigger
and/or amplify the neuronal damage.
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4.1.3. Implications of Gut Microbiota in Alzheimer’s Disease (AD)
AD is a chronic neurodegenerative disease characterized by synapses loss and neuronal death
leading to a progressive decline in cognitive function, loss of memory and, lately, to dementia.
Deposition of amyloid beta peptide (Aβ) in plaques and accumulation of hyperphosphorylated tau in
the so-called neurofibrillary tangle (NFT) are the main hallmarks of AD [134].
The mechanisms underlying these toxic depositions, which lead to an increased
neuro-inflammation, are not fully understood, but it has been supposed an important role of the gut
microbiota in this context [135].
Cattaneo et al. highlighted a close connection between brain amyloidosis and pro-inflammatory
gut bacterial taxa. Following a deep metagenomics approach, patients with cognitive amyloidosis
damage showed higher levels of pro-inflammatory cytokines, a rectal Eubacterium deficiency (known for
the peculiar anti-inflammatory function) and an overabundance of Escherichia/Shigella, when compared
to healthy patients. [19].
In GF Aβ precursor protein (APP) transgenic mouse model, a remarkable reduction of cerebral
Aβ amyloid deposition has been shown when compared to control mice with intestinal microbiota.
The absence of intestinal microbiota caused a significantly decreased cerebral Aβ amyloid
pathology. Based on 16rRNA sequencing, the colonization experiments showed the importance
of the nature of the donor (diseased transgenic versus wild-type model) for the promotion of AD.
Thus, persistent gut microbial dysbiosis can regulate host innate immunity mechanisms that affects
Aβ amyloidosis, and, consequently, microbiota modulation can induce positive effects on neuronal
pathways, slowing down the progression of AD [33].
A recent study of Haran and colleagues has applied a metagenomics approach to comparatively
evaluate the gut microbiome of AD elders versus the stool microbiome of non-AD elders. The study
highlighted numerous microbial taxa and functional genes to be considered as predictors of AD
dementia. Specifically, AD-microbiome is characterized by a lower proportion and prevalence of
butyrate-producing bacteria along with a higher abundance of bacterial taxa commonly known to
cause proinflammatory states [17].
4.1.4. Implications of Gut Microbiota in Amyotrophic Lateral Sclerosis (ALS)
ALS is a neurodegenerative disease characterized by the death of lower and upper motor neurons
in the spinal cord, brain stem, and motor cortex, leading to progressive paralysis and weakness.
Although many factors are known to be implicated in the neuronal damage, such as microglia activated
inflammation, neurotoxicity, redox unbalance, and a severe mitochondrial dysfunction, the deep and
complex pathological mechanism affecting motor neuron is still not fully understood [111].
As widely reviewed by McCombe et al., theoretical reasons support the hypothesis of the
involvement of gut microbiota in the pathogenesis of ALS. They include the important connections
with the impaired metabolism, host immunity, and production of toxins that induce brain damage [54].
Most of the experimental evidence of gut dysbiosis comes from studies on mouse models for ALS,
such as the SOD1G93A mouse model.
A dysfunction in the intestinal tract has been highlighted in transgenic SOD1G93A mice, compared
to wild-type mice, by Wu et al. Alterations in tight junction structure at the intestinal level and
a reduced expression of the related protein (ZO-1), have been correlated to an increased intestinal
permeability enabling the passage of toxins from intestinal lumen into blood circulation [136].
In ALS mouse altered microbiome composition and function have recently been highlighted,
even before the onset of symptoms due to motor neuron dysfunction [20]. In particular, by shotgun
metagenomics and 16S rRNA gene sequencing, it has been shown that the alteration of several strains,
such as Parabaceroides distasonis, Lactobacillus gasseri, Prevotella melaninogenica, Ruminococcus torques,
Akkermansia muciniphila (AM), and others, is related to disease condition. Interestingly, AM has been
shown to decrease in a time dependent manner with the disease progression [20].
In general, a few studies have been performed on human ALS, and with conflicting results.
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Brenner et al. have compared an ALS patient group, strictly selected without symptoms
of dysphagia, gastrostomy, non-invasive ventilation, or low body mass index to an age- and
gender-matched healthy control group. The metagenomics analysis of fecal microbiota has revealed
that ALS patients do not show substantial alterations in gut microbiota composition, rather in the
total number of microbial species and in the abundance of uncultured Ruminococcaceae. The authors
concluded that ALS cannot undoubtedly be associated with a significant gut microbiota impairment [39].
Similarly, Rowin et al. showed a low diversity of intestinal microbial composition in
fecal samples of ALS compared to controls, inferring that there is no direct and significant gut
microbiota–disease correlation. Only a few ALS patients showed low Ruminococcus abundance,
and low Firmicutes/Bacteroidetes (F/R) ratio, as an indicator of dysbiosis. In contrast, most patients
showed inflammatory markers, such as fecal secretory IgA, eosinophilic protein X, and calprotectin.
The authors therefore assumed that gut-mediated inflammation is likely to be involved in ALS onset or
progression [38].
In a previous metagenomics study, a reduced Firmicutes/Bacteroides ratio has also been shown in
ALS patients along with an increase of the abundance of genus Dorea and a decrease of the abundance
of genus Oscillibacter, Anaerostripes Lachnospiraceae [37].
Conversely, Mazzini et al. highlighted an altered ALS gut microbiota by quantitative PCR
analysis. Specifically, the authors showed a cluster distinction between bacterial profiles of ALS
patients compared to controls, especially related to an increase of Escherichia coli and Enterobacteria, and
a decrease of Clostridium and yeast [40].
Fecal microbiota transplantation (FMT) has emerged as a promising strategy to restore gut
microbiota dysbiosis involved in complex pathologies including neurodegenerative diseases [137].
To this regard, a very recent paper has proposed a multicenter randomized double-blind clinical
trial employing FMT as a therapeutic intervention for ALS patients at an early stage, opening new
avenues for the treatment of neurodegenerative diseases by acting on the microbiota modulation [138].
5. Conclusions
It is nowadays well established that the gut microbiota is able to influence human health by
acting on several physiological processes. In recent years, huge efforts have been made to shed light
on the myriad of established cross-communications between the gut microbiota and distant organs,
such as the brain. There is still an open debate about whether dysbiosis is a factor that determines
neurodegeneration or rather an epiphenomenon resulting from it.
The mutual correlation has undoubtedly been confirmed by many animal and human studies.
However, this field is still in its infancy and further complementary studies are needed to address
the outstanding issues.
In this context, the integrated approach based on the potential and experimental strength of
the omics and meta-omics sciences currently opens new perspectives and provides powerful tools
to support ongoing research and clinical studies. The valuable contribution meta-omics sciences
have already made in the investigation of taxonomic characterization and functional dynamics of gut
microbiota should be acknowledged. These sciences make it possible to obtain functional data and
results not achievable with the other investigation methods available so far.
We are confident that the continuous technological progress and the development of innovative
omics-based investigation methods will allow, in the near future, even more in-depth studies on a wide
range of microbiota related disorders, including but not limited to neurodegenerative diseases.
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